Kovitz Investment Group Partners LLC Sells 12,450 Shares of Semler Scientific Inc. $SMLR

Key Points

• Kovitz Investment Group Partners LLC reduced its holdings in Semler Scientific Inc. by 54.4%, now owning 10,435 shares worth approximately $378,000.
• Analysts have varied opinions on Semler Scientific, with shares recently having a mixed rating of "buy" and "sell", and an average target price set at $81.75.
• Semler Scientific reported an EPS of $5.04 for the quarter, significantly exceeding analysts' expectations, alongside a revenue of $8.22 million.

Kovitz Investment Group Partners LLC lessened its position in Semler Scientific Inc. (NASDAQ:SMLR - Free Report) by 54.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,435 shares of the company's stock after selling 12,450 shares during the quarter. Kovitz Investment Group Partners LLC owned about 0.11% of Semler Scientific worth $378,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of SMLR. Geode Capital Management LLC raised its holdings in Semler Scientific by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 140,423 shares of the company's stock worth $7,584,000 after acquiring an additional 4,464 shares during the period. Invesco Ltd. bought a new position in shares of Semler Scientific during the 4th quarter worth about $5,964,000. Legal & General Group Plc increased its holdings in shares of Semler Scientific by 65.4% during the 4th quarter. Legal & General Group Plc now owns 2,056 shares of the company's stock worth $111,000 after purchasing an additional 813 shares during the period. Raymond James Financial Inc. bought a new position in shares of Semler Scientific during the 4th quarter worth about $1,939,000. Finally, NewEdge Advisors LLC increased its holdings in shares of Semler Scientific by 318.3% during the 4th quarter. NewEdge Advisors LLC now owns 732 shares of the company's stock worth $40,000 after purchasing an additional 557 shares during the period. Institutional investors own 49.37% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SMLR. Wall Street Zen downgraded shares of Semler Scientific from a "buy" rating to a "sell" rating in a report on Thursday, May 22nd. Maxim Group upgraded shares of Semler Scientific to a "strong-buy" rating and set a $95.00 target price on the stock in a research report on Wednesday, July 9th. Benchmark initiated coverage on shares of Semler Scientific in a research report on Tuesday, July 8th. They set a "buy" rating and a $101.00 target price on the stock. Finally, Cantor Fitzgerald reduced their price target on shares of Semler Scientific from $61.00 to $60.00 and set an "overweight" rating on the stock in a research report on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the company. Based on data from MarketBeat, Semler Scientific presently has an average rating of "Buy" and an average price target of $81.75.

Semler Scientific Price Performance

Shares of NASDAQ SMLR traded up $1.33 during trading on Friday, reaching $31.43. The company had a trading volume of 847,315 shares, compared to its average volume of 583,280. Semler Scientific Inc. has a 52 week low of $21.77 and a 52 week high of $81.56. The stock has a market cap of $465.48 million, a PE ratio of 12.93 and a beta of 1.34. The company has a debt-to-equity ratio of 0.25, a quick ratio of 0.58 and a current ratio of 0.60. The business's 50 day moving average price is $37.49 and its 200-day moving average price is $37.75.

Semler Scientific (NASDAQ:SMLR - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $5.04 earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $5.31. Semler Scientific had a net margin of 86.20% and a return on equity of 43.84%. The company had revenue of $8.22 million during the quarter, compared to the consensus estimate of $8.10 million.

Semler Scientific Profile

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.